

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-17. (Cancelled).

18. (Currently amended) An immunogenic composition comprising antigen-presenting cells; ; a human stress protein selected from the group consisting of a heat shock protein or a heat shock fusion protein containing a Hsp70 C-terminal fragment and a fusion protein containing both the Hsp70 C-terminal fragment and a human antigen, the Hsp70 C-terminal fragment being encoded by a DNA molecule flanked by 5'-GCGATGCCAACGGCATCCTGAAC-3' or a degenerate sequence thereof and 5'-CTAATCTACCTCCTCAATGGTG-3' or a degenerate sequence thereof; and a pharmaceutically acceptable carrier-, wherein the composition is free of any human antigen that is not covalently bound.

19. (Original) The immunogenic composition of claim 18, wherein the antigen-presenting cells include dendritic cells.

20. (Original) The immunogenic composition of claim 19, wherein the antigen-presenting cells are purified.

21. (Currently amended) The immunogenic composition of claim 20, wherein the heat shock protein is Hsp70 and the ~~heat shock fusion protein contains~~ human antigen is alpha-fetal protein or prostate specific antigen.

22. (Original) The immunogenic composition of claim 18, wherein the antigen-presenting cells are purified.

23. (Currently amended) The immunogenic composition of claim 18, wherein the ~~heat shock fusion protein contains~~ human antigen is a tumor associated antigen, ~~a polypeptides encoded by an oncogene or a fragment thereof, or a tumor suppressor protein or a fragment thereof.~~

24. (Original) The immunogenic composition of claim 18, further comprising a cytotoxic compound.

25. (Original) The immunogenic composition of claim 24, wherein the antigen-presenting cells include dendritic cells.

26. (Original) The immunogenic composition of claim 24, wherein the antigen-presenting cells are purified.

27. (Currently amended) The immunogenic composition of claim 24, wherein the ~~heat shock fusion protein contains~~ human antigen is a tumor associated antigen, ~~a polypeptides encoded by an oncogene or a fragment thereof, or a tumor suppressor protein or a fragment thereof.~~

28-35. (Cancelled).

36. (New) The immunogenic composition of claim 18, wherein the stress protein is a heat shock fusion protein.

37. (New) The immunogenic composition of claim 36, wherein the human antigen is a tumor associated antigen.

38. (New) The immunogenic composition of claim 37, wherein the human antigen is a prostate specific antigen.

39. (New) The immunogenic composition of claim 37, wherein the human antigen is an alpha-fetal protein.

40. (New) The immunogenic composition of claim 18, wherein the Hsp70 C-terminal fragment is encoded by a DNA molecule flanked by 5'-GCGATGCCAACGGCATCCTGAAC-3' and 5'-CTAATCTACCTCCTCAATGGTG-3'.

41. (New) The immunogenic composition of claim 40, wherein the stress protein is a heat shock protein.

42. (New) The immunogenic composition of claim 41, wherein the heat shock protein is Hsp70.

43. (New) The immunogenic composition of claim 40, wherein the stress protein is a heat shock fusion protein.

44. (New) The immunogenic composition of claim 43, wherein the human antigen is a tumor associated antigen.

45. (New) The immunogenic composition of claim 44, wherein the human antigen is a prostate specific antigen.

46. (New) The immunogenic composition of claim 44, wherein the human antigen is an alpha-fetal protein.